Verastem (2VSA) Stock Overview
A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2VSA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Verastem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.69 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$2.88 |
| Beta | 0.29 |
| 1 Month Change | 15.91% |
| 3 Month Change | -19.72% |
| 1 Year Change | -3.32% |
| 3 Year Change | 290.79% |
| 5 Year Change | -89.92% |
| Change since IPO | -96.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VSA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 22.4% | 1.5% | 3.8% |
| 1Y | -3.3% | 16.6% | 3.9% |
Return vs Industry: 2VSA underperformed the German Biotechs industry which returned 16.6% over the past year.
Return vs Market: 2VSA underperformed the German Market which returned 3.9% over the past year.
Price Volatility
| 2VSA volatility | |
|---|---|
| 2VSA Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 2VSA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2VSA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 102 | Dan Paterson | www.verastem.com |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205.
Verastem, Inc. Fundamentals Summary
| 2VSA fundamental statistics | |
|---|---|
| Market cap | €345.73m |
| Earnings (TTM) | -€169.58m |
| Revenue (TTM) | €43.35m |
Is 2VSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VSA income statement (TTM) | |
|---|---|
| Revenue | US$49.59m |
| Cost of Revenue | US$7.37m |
| Gross Profit | US$42.21m |
| Other Expenses | US$236.17m |
| Earnings | -US$193.96m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.21 |
| Gross Margin | 85.13% |
| Net Profit Margin | -391.16% |
| Debt/Equity Ratio | 101.1% |
How did 2VSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/05 22:05 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verastem, Inc. is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Matthew Cross | Alliance Global Partners |
| George Zavoico | B. Riley Securities, Inc. |